QYUNS-B (02509) Announces Monthly Return for February 2026

Bulletin Express
03/05

Qyuns Therapeutics Co., Ltd. reported that, as of 28 February 2026, its authorized share capital remained at 227.07 million shares with a par value of RMB 1, totaling RMB 227.07 million. Issued shares (excluding treasury shares) decreased from 224.87 million to 224.57 million, while treasury shares increased from 2.20 million to 2.50 million. Overall, the total number of shares remained 227.07 million.

According to the announcement, 307,000 shares were repurchased on 2, 3, 4, and 6 February 2026 at prices ranging from HKD 20.12 to HKD 20.24. These repurchased shares were held as treasury shares, and the applicable public float requirement continued to be met. No other movements in issued shares, convertible securities, or share options were recorded for the period.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10